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Abstract
Aims/hypothesis Carbohydrate-free diet prevents hypergly-
caemia and beta cell destruction in the New Zealand Obese
(NZO) mouse model. Here we have used a sequential
dietary regimen to dissociate the effects of obesity and
hyperglycaemia on beta cell function and integrity, and to
study glucose-induced alterations of key transcription
factors over 16 days.
Methods Mice were rendered obese by feeding a
carbohydrate-free diet for 18 weeks. Thereafter, a
carbohydrate-containing diet was given. Plasma glucose,
plasma insulin and total pancreatic insulin were determined,
and forkhead box O1 protein (FOXO1) phosphorylation
and the transcription factors pancreatic and duodenal
homeobox 1 (PDX1), NK6 homeobox 1 protein
(NKX6.1) and v-maf musculoaponeurotic fibrosarcoma
oncogene family, protein A (avian) (MAFA) were moni-
tored by immunohistochemistry for 16 days.
Results Dietary carbohydrates produced a rapid and con-
tinuous increase in plasma glucose in NZO mice between
day 2 and 16 after the dietary challenge. Hyperglycaemia
caused a dramatic dephosphorylation of FOXO1 at day 2,
followed by a progressive depletion of insulin stores. The
loss of beta cells was triggered by apoptosis (detectable at
day 8), associated with reduction of crucial transcription
factors (PDX1, NKX6.1 and MAFA). Incubation of isolated
islets from carbohydrate-restricted NZO mice or MIN6 cells
with palmitate and glucose for 48 h resulted in a
dephosphorylation of FOXO1 and thymoma viral proto-
oncogene 1 (AKT) without changing the protein levels of
both proteins.
Conclusions/interpretation The dietary regimen dissociates
the effects of obesity (lipotoxicity) from those of hyper-
glycaemia (glucotoxicity) in NZO mice. Obese NZO mice
are unable to compensate for the carbohydrate challenge by
increasing insulin secretion or synthesising adequate
amounts of insulin. In response to the hyperglycaemia,
FOXO1 is dephosphorylated, leading to reduced levels of
beta cell-specific transcription factors and to apoptosis of
the cells.
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Obese rodents with susceptibility for hyperglycaemia such
as the C57BKS/J-db/db (diabetic) and the New Zealand
Obese (NZO) mouse have been studied as models for the
human obesity-associated type 2 diabetes [1–3]. These
strains present a progressive failure of insulin-secreting beta
cells, and a severely decompensated glucose homeostasis
with glucosuria and blood glucose levels >20 mmol/l. By
conventional cross-breeding experiments, genomic seg-
ments (diabetogenic quantitative trait loci) were identified
that are responsible for the decompensation of glucose
homeostasis [4–8]. As predicted earlier [2, 9], these
diabetogenic alleles were contributed from the obese as
well as from the lean (background) strains. More recently,
three candidate genes for beta cell failure in obese mice,
Sorcs1, Lisch-like (Ildr2) and Zfp69 [10–12], and one
candidate suppressor of diabetes, Tbc1d1 [13], have been
identified by positional cloning.
It is generally accepted that beta cell malfunction is
caused by the following scenario. Obesity induces ectopic
fat accumulation in the pancreas, thereby causing apoptosis
of beta cells (‘lipotoxicity’)[ 14–16]. Data from NZO mice
showing that dietary fat, in combination with the presence
of diabetogenic alleles, markedly increases the prevalence
of diabetes are consistent with such a scenario [6]. In
addition, the prevalence of diabetes in NZO is reduced
when fat oxidation in muscle is stimulated by disruption of
Tbc1d1 [13]. However, lipotoxicity does not appear to be
sufficient for the destruction of the beta cell. Carbohydrate-
restricted diets fully prevented beta cell destruction in both
NZO and db/db mice [17, 18] despite an extreme insulin
resistance and a marked inflammatory state of adipose
tissue [19]. This finding is consistent with a previously
suggested scenario in which postprandial hyperglycaemia
(‘glucotoxicity’) plays an essential role in the pathogenesis
of islet cell failure [20, 21].
Hyperglycaemia produces glucotoxicity for the beta
cell through oxidative stre s sc a u s e db yf o r m a t i o no f
reactive oxygen species [22]. This mechanism has been
investigated in cultured beta cell lines, and is assumed to
initially involve specific transcription factors controlling
the insulin gene, such as pancreatic and duodenal
homeobox 1 (PDX1) and v-maf musculoaponeurotic
fibrosarcoma oncogene family, protein A (avian) (MAFA),
and subsequently the proliferation of the cells [23, 24].
The two scenarios, lipotoxicity and glucotoxicity, are not
mutually exclusive but may function in combination
[25, 26].
In the present study, we employed the NZO mouse
model to dissociate the effects of dietary lipids and dietary
carbohydrates in vivo, and to study the time course of beta
cell failure. NZO mice were exposed to a carbohydrate-free
diet until the age of 18 weeks in order to produce obesity
and insulin resistance without hyperglycaemia or diabetes.
Thereafter, carbohydrates were added to the diet, and
variables of beta cell function were monitored for 16 days.
Our data indicate that the dietary carbohydrates rapidly
produced hyperglycaemia, paralleled by dephosphorylation
of forkhead box O1 protein (FOXO1), and followed by
internalisation of glucose transporter type 2 (GLUT2) and
progressive decrease of the pancreatic insulin content. In
a second phase of the decompensation, plasma insulin
levels decreased sharply, further aggravating hypergly-
caemia, and nuclear staining of the transcription factors
PDX1, NK6 homeobox 1 protein (NKX6.1) and MAFA
decreased markedly. These results indicate that the
dietary regimen of initial carbohydrate restriction and
subsequent refeeding dissociates lipotoxicity and gluco-
toxicity. In addition, they suggest a scenario in which a
hyperglycaemia-induced loss of FOXO1 plays a crucial
role in a progressive malfunction of the transcriptional
machinery of the beta cell.
Methods
Experimental animals Male NZO/HIBomDife mice (R.
Kluge, German Institute of Human Nutrition, Nuthetal,
Germany) from our own colony were housed in groups of
five per cage (type II macrolon) at a temperature of 21±1°C
with a 12 h light–dark cycle (lights on at 06:00 hours).
Animals had free access to food and water, and were kept in
accordance with the National Institutes of Health guidelines
for the care and use of laboratory animals. All experiments
were approved by the Ethics Committee of the State
Ministry of Agriculture, Nutrition and Forestry (State of
Brandenburg, Germany).
Diets and study design From weaning at the age of 3 weeks
onwards, mice received a carbohydrate-free pelleted diet
purchased from Altromin (custom made by the manufac-
turer, Lage, Germany), containing (wt/wt) 30.2% fat and
26.4% protein with a total metabolisable energy of 15.3 kJ/g.
Fat content normalised per total energy was 72.2% and
protein content was 27.8%. Because of the soft texture of the
diet, mice had access to wooden gnawing sticks in order to
avoid excessive teeth growth.
At the age of 18 weeks, mice were randomised to either a
carbohydrate-containing diet or continued on a carbohydrate-
free diet for up to an additional 16 days (Fig. 1). The
ingredients of the diets are given in the Electronic
606 Diabetologia (2011) 54:605–616supplementary material (ESM) Table 1 and percentages of
macronutrients plus energy density are given in ESM Table 2.
Blood samples were collected at the indicated days from the
tail vein of fed mice between 09:00 hours and 11:00 hours.
Blood glucose was determined with an Ascensia ELITE XL
glucose meter (Bayer Health Care, Leverkusen, Germany).
Plasma insulin was assayed with the Mouse Insulin
Ultrasensitive ELISA kit (DRG Instruments, Marburg,
Germany). Body composition (fat and lean mass) was
measured before the start of the diet change by nuclear
magnetic resonance with an EchoMRI Whole Body Com-
position Analyzer (Echo Medical Systems, Houston, TX,
USA) as previously described [19, 27, 28].
Pancreatic insulin content For detection of total pancreas
insulin, whole pancreases were homogenised in ice-cold
acid ethanol (0.1 mol/l HCl in 70% ethanol) and
i n c u b a t e d2 4ha t4 ° C .A f t e rc e n t r i f u g a t i o n( 1 6 , 0 0 0 g,
10 min) insulin was detected in the supernatant fraction
with the Mouse Insulin Ultrasensitive ELISA kit (DRG
Instruments).
Immunohistochemistry of pancreatic islets Pancreatic tis-
sue excised immediately after exsanguination was fixed
in 4% formaldehyde for 24 h, embedded in paraffin
according to standard procedures, and longitudinal serial
sections (2 μm, at three sampling intervals of 100 μm)
were prepared.
For immunostaining of insulin, sheep anti-insulin anti-
serum (1:6,000; Vector Laboratories, Burlingame, CA, USA)
was used, followed by biotinylated donkey anti-sheep IgG
antiserum (1:800, Jackson ImmunoResearch Labs, Newmar-
ket, UK). The secondary antibody was detected with
streptavidin–biotin–alkaline peroxidase complex (StreptAB-
complex/HRP; Dako, Hamburg, Germany) and diaminoben-
zidine (DAB) as substrate according to the manufacturer’s
specifications.
Proinsulin was immunostained with mouse anti-
proinsulin antibody (1:50; GS-9A8 Developmental Stud-
ies Hybridoma Bank, Iowa City, IA, USA), followed by
biotinylated donkey anti-mouse IgG antiserum (1:800,
Jackson ImmunoResearch Labs), and detection with
DAB as substrate.
For immunostaining of glucagon, phosphorylated
FOXO1 (pFOXO1), PDX1, NKX6.1, caspase-3 and
MAFA, rabbit anti-glucagon antiserum (1:2,000; DAKO
Diagnostika, Hamburg, Germany), rabbit anti-pFOXO1
(Thr24)/FoxO3a (Thr32) antibody (1:50; Cell Signal-
Fig. 1 Carbohydrate refeeding causes rapid onset of hyperglycaemia
and delayed decompensation of insulin secretion in NZO mice. a
Study design for the application of carbohydrate-restricted (−CH) and
carbohydrate-containing diets (+CH). Until week 18, obesity and
insulin resistance was produced by application of a carbohydrate-free
diet. Thereafter, a high-carbohydrate (black squares) or a
carbohydrate-free diet (white squares) was given for 16 days. b, c
Time course of (b) blood glucose and (c) plasma insulin after the diet
change. Samples were collected at the indicated time points, and data
represent mean±SEM of at least ten mice
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Solutions, Charlottesville, VA, USA), mouse anti-
NKX6.1 (1:2,000, F55A10, Developmental Studies
Hybridoma Bank, Iowa City, IA, USA), rabbit anti-
active caspase 3 (1:100; Promega, Mannheim, Germany)
or rabbit anti-MAFA antiserum (1:1,000, Bethyl Labs,
Montgomery, AL, USA) was used, respectively. The
primary antibodies were detected with Histofine Anti-
Rabbit Immuno-POD Polymer for mouse tissues
(Nichirei Biosciences, Tokyo, Japan) and DAB as
peroxidase (POD) substrate after Histofine incubation.
GLUT2 was detected with rabbit antiserum against
the C-terminus of rat GLUT2 (1:1,000) [29]a n dA l e x a
Fluor 488 labelled goat anti-rabbit-IgG antiserum (1:200,
Invitrogen, Karlsruhe, Germany) as secondary antibody
which was visualised by stimulation of fluorescence at
488 nm.
Microscopic investigation and photo documentation
were performed with the combined light and fluorescence
microscope ECLIPSE E-100 (Nikon, Düsseldorf, Germany)
in combination with the video camera CCD-1300CB
(Vosskühler, Osnabrück, Germany) and the Analysis Sys-
tem LUCIA (Nikon).
Quantitative analysis of islet morphology Longitudinal
sections of pancreas co-stained with anti-insulin and anti-
glucagon antiserum were analysed with the Lucia G image
analysis software (Laboratory Imaging, Prague, Czech
Republic) via an unbiased stereological approach. In three
to six sections from each mouse, a total of 35 islets were
analysed with regard to number of immunoreactive cells
(insulin and glucagons) and number of PDX-, NKX6.1- and
MAFA-positive nuclei. Mean values derived from each
individual mouse were used to calculate means±SEM of
three to six mice in each group.
In vitro experiments with isolated islets from NZO
mice Islets of 18 week old NZO mice were isolated by
ductal collagenase distension/digestion of the pancreas
using a modified method of Gotoh et al. [30]. Briefly,
3 ml of Collagenase-P (Roche, Mannheim, Germany),
1 mg/ml in Hanks’ buffered salt solution (HBSS) contain-
ing 25 mmol/l HEPES and 0.5% (wt/vol.) BSA, were
injected in the pancreas via the common bile duct. The
perfused pancreas was digested in 2 ml of collagenase
solution for 11 min at 37°C. Islets were collected by hand-
picking and pre-incubated for 24 h in RPMI 1640 medium
containing 11 mmol/l glucose, 10% FCS, 100 U/ml
penicillin, 100 U/ml streptomycin in humidified 5% CO2,
95% air at 37°C. Islets were treated with different glucose
concentrations (11, 27.6, 33.2 and 38.7 mmol/l) in the
presence or absence of 0.3 mmol/l palmitic acid for 48 h in
humidified 5% CO2, 95% air at 37°C (50 islets/group).
Western blot experiments Protein was extracted with a
cell lysis buffer (20 mmol/l Tris, 150 mmol/l NaCl,
1 mmol/l EDTA, 1 mmol/l EGTA, 1% triton-X-100,
2.5 mmol/l Na4P2O7, 1 mmol/l β-glycerolphosphate,
1m m o l / lN a 3VO4, 1 mmol/l NaF) and an additional
proteinase inhibitor cocktail tablet (per 50 ml, Roche).
Protein samples (15 μg) were separated by electrophoresis
through 10% polyacrylamide, 0.1% SDS gels, and
transferred to polyvinylidine fluoride membranes, followed
by immunoblotting. Immunodetection was developed with
ECL Advance (Amersham Biosciences, Buckinghamshire,
UK) and imaged with a C09 116 CCD camera (PEQLAB,
Erlangen, Germany). Antibodies used were: polyclonal anti-
FOXO1 (C29H4), anti-pFOXO1 (Thr24)/FoxO3a (Thr32),
anti-phosphorylated-thymoma viral proto-oncogene 1
(AKT) (Ser473) and AKT antibody (Cell Signaling,
Boston, MA, USA). At least three blots were performed
for each experiment with each blot reprobed for
glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
(anti-GAPDH, Applied Biosystems, Foster City, CA, USA)
as a loading control.
Cell culture of mouse insulinoma cells MIN6 cells were
maintained in Dulbecco’s modified Eagle’sm e d i u mc o n t a i n -
ing 5 mmol/l glucose, with 10% FCS, 100 units/ml penicillin,
100 μg/ml streptomycin and 100 μg/ml L-glutamine in
humidified 5% CO2,9 5 %a i ra t3 7 ° C[ 31]. For the
experiment MIN6 cells were treated with different glucose
concentrations (5, 10, 25 and 50 mmol/l) in the presence or
absence of 0.3 mmol/l palmitate for 48 h.
Statistical analysis Differences in body weight and blood
glucose under the different dietary regimens were tested for
statistical significance with a one-way analysis of variance
(one-way ANOVA) after verification of normal distribution,
followed by a post hoc test (homogeneous variances by
Bonferroni type and inhomogeneous variances by Games–
Howell type). All other data sets were tested with the non-
parametric Mann–Whitney U test. The calculations were
performed with the software package SPSS 14.0 (SPSS,
Chicago, IL, USA), and differences were considered
significant at p<0.05.
Results
After weaning at 3 weeks of age, all mice were fed a
carbohydrate-free pelleted diet containing (wt/wt) 30.2% fat
and 26.4% protein until the age of 18 weeks (Fig. 1a). This
dietary regimen caused massive obesity (body weight
79.8±1.2 g; body fat 31.7±0.7 g) and hyperinsulinaemia
(plasma insulin 1,229±100 pmol/l). Thereafter, mice
were randomised into two groups receiving either
608 Diabetologia (2011) 54:605–616the high-fat carbohydrate-free diet [19] or a diet contain-
ing (wt/wt) 40% carbohydrate. The composition of the
d i e t si sg i v e ni nE S MT a b l e1. After the diet change
(day 0) serum variables of glucose metabolism were
monitored over a period of 16 days. As is illustrated in
Fig. 1b,c, NZO mice on the carbohydrate-containing diet
became hyperglycaemic (>15 mmol/l) as early as 2 days
after the diet change, and hyperglycaemia continued to
increase throughout the observation period (>23 mmol/l at
day 16). Plasma insulin levels increased until day 8, but
decreased dramatically thereafter. In contrast, non-fasted
blood glucose levels in control NZO mice on the
carbohydrate-free diet remained below 11 mmol/l.
In parallel experimental series, pancreases of mice were
isolated at the indicated time points in order to monitor
insulin, proinsulin and glucagon content as well as the
number of insulin-containing cells. Figure 2 shows staining
of insulin (upper panel), and glucagon (middle panel), and
proinsulin (bottom) immunoreactivity in islets from mice
on the different diets (representative samples). Starting at
day 4, a marked reduction in the insulin content of islets was
observed. The morphometric analysis (Fig. 3a)i n d i c a t e da
significant reduction of the number of insulin-positive cells
per islet (day 8–16). At day 32, few insulin-positive cells
were detectable in islets of carbohydrate-challenged mice
(ESM Fig. 1). Thus, the immunohistochemical analysis was
Fig. 2 Immunohistochemistry
of insulin, glucagon and
proinsulin in pancreatic sections
of NZO mice after a diet change
from a carbohydrate-free
(−CH) to a carbohydrate-
containing diet (+CH). Sections
from pancreas embedded
in paraffin were haematoxylin-
stained and immunostained with
the respective antisera and
developed with DAB as
described in the Methods. Scale
bars, 50μm
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insulin between days 4 and 16, and that this depletion
accounts for the marked rise in blood glucose levels during
this time span. By staining of pancreatic sections with an
anti-caspase-3 antibody we detected a significant increase in
caspase-3-positive islet cells beginning at day 8 after
carbohydrate exposure (Fig. 3b,c), indicating that beta cells
undergo apoptosis when obese mice are exposed to
carbohydrates.
Asone ofthe limitingsteps inthesynthesis ofinsulinisthe
conversionofproinsulin,wevisualisedproinsulininbetacells
with the aid of an antibody against a peptide corresponding
with the proteolytic cleavage site; this antibody detects
proinsulin in the presence of insulin. As is illustrated in
Fig. 2 (lower panel), immunoreactive proinsulin appeared
unaltered from day 0 until day 8 after the diet change. After
day 8, immunoreactive proinsulin decreased to almost
undetectable levels, in parallel with the decrease in plasma
insulin. This finding is consistent with the conclusion that
the synthesis of proinsulin, but not its processing, was
reduced in mice after refeeding of carbohydrates.
In order to validate that data obtained by immunohisto-
chemistry, we determined the insulin content of total
pancreas by immunoassay of acidic ethanol extracts
(Fig. 4). A significant decrease of the insulin content in
response to the carbohydrate-containing diet was detected
as early as 4 days after the diet change. Thus, a gradual
decrease in total pancreatic insulin appeared to precede the
fall in plasma insulin levels.
We and others have previously reported that GLUT2
abundance is reduced and its subcellular distribution is
altered in NZO mice [19, 32]. Thus, we studied the time
course of these alterations after feeding the carbohydrate-
containing diet. As is illustrated in ESM Fig. 2, GLUT2
was predominantly localised in plasma membranes of beta
cells at day 0, and at all subsequent time points, when mice
received the carbohydrate-free diet. In contrast, GLUT2
was redistributed to intracellular compartments in islets
from carbohydrate-fed mice. This re-distribution started at
day 4 after the diet change, clearly after hyperglycaemia
had established (day 2).
As FOXO1 is an important effector of insulin action in
pancreatic beta cells and links insulin signalling to the
regulation of beta cell mass [33], we investigated levels of
pFOXO1 during the carbohydrate intervention. Strikingly,
immunoreactivity of pFOXO1 was dramatically decreased as
early as 2 days after changing the diet from carbohydrate-
free to a carbohydrate containing diet (Fig. 5a).
In order to provide direct evidence for the causal role of
hyperglycaemia (glucotoxicity), we incubated isolated islets
from carbohydrate-restricted NZO mice with different
glucose concentrations (11.1, 27.6, 33.2 and 38.7 mmol/l)
Fig. 3 Reduction of the number
of insulin-positive cells.
a Morphometric determination
of the relative number of cells
per μm
2 islet area after the diet
change from a carbohydrate-free
(white bars) to a carbohydrate-
containing (black bars) diet.
From each mouse, 35 islets in
one to six pancreatic sections
were evaluated in a blinded
procedure. b Immunostaining of
activated caspase-3 in islets of
NZO mice treated with (+CH)
or without (−CH) carbohydrates
for 8 and 16 days. c Quantifica-
tion of caspase-3-positive cells
from NZO mice fed the
indicated diets. Data represent
mean±SEM of three to six mice,
calculated from the mean values
of the individual mice. *p<0.05
for –CH vs +CH at the indicated
time point
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Lysates of the islets were analysed by western blotting with
anti-FOXO1 and anti-pFOXO1 antibodies (Fig. 5b, c).
Treatment of islets with the combination of glucose (11.1 to
38.7 mmol/l) and palmitate resulted in reduced levels of
pFOXO1, whereas the total amount of FOXO1 protein was
not altered. A similar effect was obtained for AKT; its
phosphorylation was markedly reduced after incubation of
islets with glucose concentrations of ≥27.6 mmol/l when
0.3 mmol/l palmitate was present (Fig. 5b, d). These data
suggest that pFOXO1 and pAKT were reduced by exposure
of islets to high glucose concentration, and that this effect
was dependent on the presence of palmitate.
In order to verify this finding in a second system, we
used mouse insulinoma cells (MIN6) and incubated them
with increasing concentrations of glucose (5, 10, 25 and
50 mmol/l) in the presence and absence of palmitate
Fig. 4 Carbohydrate-containing diet causes decrease of pancreatic
insulin in NZOmice.Acarbohydrate-freedietwasgivenuntilweek18in
order to produce obesity and insulin resistance. Thereafter, a
carbohydrate-containing (black bars) or a carbohydrate-free diet (white
bars) was given for 16 days. Whole pancreas was dissected at the
indicated time points, and insulin was extracted and determined as
described in the Methods. Data represent mean±SEM of six mice;
*p<0.05 for carbohydrate-containing vs carbohydrate-free diet
Fig. 5 Reduced levels of
pFOXO1 after carbohydrate
intervention. a Immunohisto-
chemistry of pFOXO1 in
pancreatic sections of NZO mice
after a diet change from a
carbohydrate-free (−CH) to a
carbohydrate-containing diet
(+CH). Sections embedded in
paraffin at the indicated day
were stained with haematoxylin
and anti-pFOXO1 and subse-
quently developed with DAB as
described in Methods. Bars:
50μm. b Western blot analysis
of lysates of isolated islets from
carbohydrate-free fed NZO mice
after in vitro incubation with the
indicated glucose concentrations
in the absence or presence of
0.3 mmol/l palmitate. c, d
Quantification of western blot
products of lysates from three
independent experiments as
shown in b. c Ratio of
pFOXO1/total FOXO1 and d
ratio of pAKT/total AKT. Values
represent mean±SEM; *p≤0.05,
†p=0.06 for absence (white
bars) vs presence (black bars) of
0.3 mmol/l palmitate at the
indicated glucose concentration
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decreased slightly when the cells were incubated with
10 mmol/l glucose in the presence of 0.3 mmol/l palmitate
for 48 h. A further increase in the glucose concentration up
to 50 mmol/l totally abolished pFOXO1. Under these
conditions, the levels of pAKT were also significantly
reduced. In contrast, exposure of MIN6 cells with increasing
concentrations of glucose in the absence of palmitate did not
influence the phosphorylation status of FOXO1 or AKT. In
order to test whether palmitate alone affects phosphorylation
of FOXO1 and AKT, we incubated MIN6 cells with
increasing concentrations of palmitate in the absence or
presence of 50 mmol/l glucose. Only the exposure of MIN6
cells with glucose plus palmitate resulted in a dose-
dependent decrease of the amount of pFOXO1 and pAKT,
whereas incubation with palmitate alone did not show
differences (Fig. 6d–f).
According to the early dephosphorylation of FOXO1,
the nuclear staining of PDX1 (Fig. 7a, b), NKX6.1
(Fig. 7c,d) and MAFA (ESM Fig. 3) was decreased later
(day 8–16), in parallel with the decrease in plasma insulin
levels.
Fig. 6 Reduced levels of
pFOXO1 and pAKT in MIN6
cells in response to glucose and
palmitate exposure. a Western
blot analyses of lysates from
MIN6 cells incubated with the
indicated glucose concentrations
in the absence or presence of
0.3 mmol/l palmitate for 48 h
were performed with the indi-
cated antibodies as described in
Methods. b, c Quantification of
western blot products of lysates
from three independent experi-
ments as shown in a: pFOXO1/
total FOXO1 (b) and ratio of
pAKT/total AKT (c). *p≤0.05
for absence (white bars) vs
presence (black bars) of palmi-
tate at the indicated glucose
concentration. d Western blot
analysis of lysates from MIN6
cells incubated with the indicat-
ed palmitate concentrations in
the absence or presence of
50 mmol/l glucose for 48 h. e, f
Quantification of western blot
products of lysates from three
independent experiments as
shown in d: Ratio of pFOXO1/
total FOXO1 (e) and ratio of
pAKT/total AKT (f). Values
represent mean±SEM; *p≤0.05
for low glucose (white bars) vs
high glucose (black bars) at the
indicated palmitate
concentration
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In this study, we present an experimental setup that allows
monitoring of beta cell failure initiated by dietary carbohy-
drates for 2–16 days. By an initial carbohydrate restriction
and subsequent refeeding, the consequences of lipotoxicity
and glucotoxicity were dissociated. During carbohydrate
restriction, NZO mice developed obesity and severe insulin
resistance, but no hyperglycaemia. Thereafter, exposure to
dietary carbohydrates rapidly produced a biphasic pattern of
beta cell failure (Fig. 8). First, an initial hyperglycaemia,
revealing an insufficiency of the pancreas to secrete
adequate amounts of insulin, was paralleled by a dramatic
dephosphorylation of FOXO1. This hyperglycaemia pro-
duced internalisation of GLUT2 and initiated a progressive
depletion of insulin stores. In a second phase (beginning at
day 8), plasma insulin levels fell dramatically, leading to
complete decompensation of glucose homeostasis at
day 16, induction of apoptosis, and thereby to the loss of
beta cells (day 32). In parallel, crucial transcription factors
(PDX1, NKX6.1, MAFA) were reduced. This sequence of
events is consistent with a scenario in which insulin
synthesis is severely affected, and beta cell destruction is
ultimately caused by the progressive hyperglycaemia
(glucotoxicity).
Among the markers of beta cell function we monitored,
pFOXO1 was the first to respond to the dietary change in
that its immunoreactivity was markedly reduced at the
earliest time point studied (day 2). This alteration was
detected by immunohistochemistry, which is a qualitative
method not allowing quantification. Furthermore, the in
vivo experiments suggest, but do not prove, a causal role of
the hyperglycaemia. Thus, we obtained direct evidence for
the effect of hyperglycaemia on FOXO1 by isolation of
Fig. 7 Immunohistochemistry and quantification of PDX1 (a, b) and
NKX6.1 (c, d) in pancreatic sections of NZO mice after a diet change
from carbohydrate-free (−CH) (white bars) to carbohydrate-containing
diet (+CH) (black bars). (a, c) Sections embedded in paraffin at the
indicated day were haematoxylin-stained and immunostained with the
respective antiserum and developed with DAB as described in
Methods. Scale bars, 50μm. (b, d) Quantifications of nuclei positive
for PDX1 (b) and NKX6.1 (d) were performed for three to six mice
per group; *p≤0.05 for –CH vs +CH at the indicated time points
Reduced insulin content
Internalisation of GLUT2
Apoptosis
Dephosphorylation
of FOXO1
Carbohydrate-free diet
Week 18
Diet change: refeeding 
of carbohydrates
Day 2 Day 4 Day 8 Day 16
Plasma insulin
Blood glucose
Beta cell loss Reduced number of PDX1–
and NKX6.1–positive nuclei
Fig. 8 Schematic presentation of the time course of events leading to
beta cell loss in NZO mice after carbohydrate refeeding
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in the absence and presence of palmitate. With this
approach, we provided direct evidence for role of hyper-
glycaemia (glucotoxicity) in the AKT–FOXO1 pathway,
because we detected reduced levels of pFOXO1 and pAKT
in islets treated with high glucose concentrations in the
presences of palmitate (Fig. 5b). This finding was con-
firmed in a second system, MIN6 cells, which exhibited a
reduction in pFOXO1 and pAKT when treated with glucose
plus palmitate but not with palmitate alone (Fig. 6), clearly
demonstrating that not fatty acids alone but glucose, in
combination with fatty acids, produces inactivation of the
AKT–FOXO1 pathway.
FOXO1 is a transcription factor that is excluded from
nuclei upon phosphorylation by AKT/PKB via the insulin/
insulin-like growth factor-I pathway [34–36]; a conse-
quence of this exclusion is the rapid induction of the
insulin gene, and a stimulation of beta cell proliferation.
Disruption of AKT–FOXO1 signalling might be responsible
for the apoptosis of beta cells (Fig. 3b,c). Our data do not
show which apoptotic pathway is induced, and do not
provide direct evidence for a causal role of FOXO1 in beta
cell death. However, one can speculate that a dephosphor-
ylation of AKT and FOXO1 downregulates survival path-
ways and/or induces transcription of apoptotic proteins such
as BCL2-associated X protein (BAX) [37]. In addition, as it
was suggested that dephosphorylated FOXO1 inhibits the
transcription of Pdx1 through competing the binding sites
with FOXA2 [33, 38] one could speculate that FOXO1
binds to the Pdx1 promoter and inhibits PDX1 and finally
insulin production in response to hyperglycaemia. However,
we also do not provide direct evidence for this kind of
regulation. Accordingly, we observed a reduced content of
PDX1 and other downstream transcription factors (NKX6.1
and MAFA) at later time points of carbohydrate intervention.
Chronic hyperglycaemia was previously shown to induce a
progressive loss of beta cell phenotype and of insulin
secretory function with decreased production of beta cell-
specific transcripts such as insulin, NKX6.1, hepatic nuclear
factor-α (HNFα) and GLUT2 [39]. Our finding might
indicate that an early modification induced by exposure of
beta cells to elevated concentrations of glucose is the
alteration of the phosphorylation status of FOXO1 protein
which finally results in a ‘de-differentiation’ of the beta cells.
It should be noted that, in addition to hyperglycaemia,
other confounding factors such as insulin resistance have
contributed to the beta cell failure in NZO mice. NZO mice
receiving the carbohydrate-restricted high-fat diet were
severely insulin resistant, as shown by euglycaemic–hyper-
insulinaemic clamp experiments [19]. This severe insulin
resistance, together with the dietary carbohydrates, produced
a metabolic challenge that could not be compensated by the
beta cell. Furthermore, the glycaemic control decompensated
rapidly after refeeding carbohydrates. This finding indicates
an inability of the beta cell to secrete adequate amounts of
insulin which has developed in the absence of dietary
carbohydrates. Consequently, lipid accumulation in beta cells
could be responsible for their initial malfunction. However,
these considerations do not alter the conclusion that hyper-
glycaemia was required for apoptosis and loss of beta cells,
although it may not have been sufficient. The model we
present here is suitable for the identification of the lipid-
induced abnormalities in beta cells, and for their dissociation
from the ‘toxic’ effect of elevated blood glucose.
The protective effect of the carbohydrate-free diet has been
observed in two mouse strains, NZO and db/db [17–19]. In
both strains, beta cell failure was associated with a marked
decrease in the immunoreactivity of the GLUT2 [18, 19].
Internalisation and reduced abundance of GLUT2 in beta
cells of NZO mice and in other models of diabetes (Chinese
hamster and Psammomys obesus) has been reported earlier
to precede the loss of insulin immunoreactivity [32, 40, 41].
Here, a reduction of GLUT2 immunoreactivity in plasma
membranes was detected at day 4, apparently after the onset
of hyperglycaemia. Thus, internalisation of GLUT2 is a
consequence of hyperglycaemia rather than its cause.
Elevated proinsulin levels in serum and beta cells have
been reported for another rodent model of type 2 diabetes,
Psammomys obesus [42]. Thus, it was suggested that a
block in the conversion of the pro-hormone to insulin is the
cellular mechanism of inadequate insulin secretion in this
model. In our model, beta cells were depleted of proinsulin
and insulin in parallel, suggesting that the synthesis of
proinsulin, rather than its processing, is inadequate.
In summary, our data present a novel experimental
model for the in vivo monitoring of alterations leading to
beta cell failure in obese mice. The dietary regimen of
carbohydrate restriction and refeeding dissociates the
effects of obesity (lipotoxicity) from those of hyperglycae-
mia (glucotoxicity) in NZO mice. With this model, we
show that a dietary carbohydrate challenge causes an early
and dramatic decrease in pFOXO1. Obese NZO mice are
unable to compensate the challenge by increased insulin
secretion, and to synthesise adequate amounts of insulin. In
a second phase, the progressive hyperglycaemia depletes
beta cells of insulin and causes loss of transcription factors
that are critical for their function and survival.
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